# Amanda Nickles Fader

Source: https://onco.cc/people/amanda-fader/  
OnCo record `amanda-fader` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer.

## Summary

Amanda Nickles Fader is a gynaecologic oncologist at Johns Hopkins. She was first author of the 2018 Journal of Clinical Oncology report of the randomised phase 2 trial in which adding trastuzumab to carboplatin and paclitaxel lengthened progression-free survival in advanced or recurrent HER2/neu-positive uterine serous carcinoma, a result that entered guidelines. Her research also covers minimally invasive surgery and rare gynaecological cancers.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: endometrial; gynaecological; trialist
- Role: Gynaecologic oncologist, Johns Hopkins
- Specialisms: Uterine serous carcinoma; HER2-directed therapy; Minimally invasive gynaecologic surgery

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [p53-abnormal endometrial cancer, including uterine serous carcinoma](https://onco.cc/cancers/endometrial-p53-abnormal/)
- institutions: [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://onco.cc/institutions/johns-hopkins/)
- key papers: [Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma](https://onco.cc/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/)

---
JSON: https://onco.cc/api/v1/entities/amanda-fader.json